LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

Accueil・Liste d'Actions・Johnson and Johnson

Johnson and Johnson

Fermé

SecteurSoins de santé

225.18 -2.6

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

224.5

Max

225.94

Chiffres clés
By Trading Economics
Revenu	119M 5.2B
Ventes	-502M 24B
P/E Moyenne du Secteur	27.186 50.102
BPA	2.7
Rendement du dividende	2.24
Marge bénéficiaire	21.756
Employés	138,200
EBITDA	182M 6.4B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+15.42% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	2.24% 2.33%
Prochains Résultats	15 juil. 2026
Date du Prochain Dividende	9 juin 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-9.4B 564B
Ouverture précédente	227.78
Clôture précédente	225.18

Sentiment de l'Actualité

By Acuity

51%

49%

271 / 344 Classement par Healthcare

Johnson and Johnson Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 13:27 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23 avr. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22 avr. 2026, 11:27 UTC

Résultats

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14 avr. 2026, 19:38 UTC

Résultats

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 avr. 2026, 14:13 UTC

Résultats

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 avr. 2026, 12:57 UTC

Résultats

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 avr. 2026, 11:19 UTC

Résultats

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 avr. 2026, 10:34 UTC

Résultats

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14 avr. 2026, 10:20 UTC

Market Talk

Résultats

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14 avr. 2026, 10:20 UTC

Market Talk

Résultats

J&J's Tremfya Sales Continue to Surge -- Market Talk

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14 avr. 2026, 10:20 UTC

Résultats

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Comparaison

Variation de prix

Johnson and Johnson prévision

Objectif de Prix

By TipRanks

15.42% hausse

Prévisions sur 12 Mois

Moyen 266.4 USD 15.42%

Haut 285 USD

Bas 250 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

17 ratings

Achat

Maintien

Vente

Basé sur 17 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

271 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.